|
|
Volumn 67, Issue 15, 2010, Pages 1221-1222
|
|
Growth of REMS challenges FDA, stakeholders
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
RECOMBINANT ERYTHROPOIETIN;
TOCILIZUMAB;
PRESCRIPTION DRUG;
DRUG APPROVAL;
DRUG MANUFACTURE;
DRUG MARKETING;
DRUG SURVEILLANCE PROGRAM;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
NOTE;
PRIORITY JOURNAL;
RISK EVALUATION AND MITIGATION STRATEGY;
LEGAL ASPECT;
METHODOLOGY;
PATIENT EDUCATION;
POSTMARKETING SURVEILLANCE;
RISK ASSESSMENT;
UNITED STATES;
HUMANS;
PATIENT EDUCATION AS TOPIC;
PRESCRIPTION DRUGS;
PRODUCT SURVEILLANCE, POSTMARKETING;
RISK ASSESSMENT;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 78349270199
PISSN: 10792082
EISSN: 15352900
Source Type: Journal
DOI: 10.2146/news100053 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
